  Immunosenescence might be expected to reduce the efficacy of checkpoint blockade , which depends on a functionally intact immune system. However , it seems that older melanoma patients may respond better to anti-PD1 treatment than younger patients , possibly due to their having fewer regulatory T-cells relative to CD8 + T-cells within tumour deposits.